össur annual report2009 - Euroland
össur annual report2009 - Euroland
össur annual report2009 - Euroland
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
R&D is essential to future development of the Company that is determined<br />
to maintain its technological competency through investment in research<br />
and development activities.<br />
intellectual property<br />
The role of intellectual property management at Össur<br />
is to implement IP strategies in alignment with the<br />
Company’s overall business objectives. IP functions<br />
are strategic alignment, portfolio management – assuring<br />
necessary freedom to commercial exploitation –<br />
licensing and IP conflict management.<br />
Össur’s intellectual property rights are generated<br />
through in-house innovation, acquisitions and user<br />
licenses. The Company’s IP portfolio is well diversified<br />
and representative of the business areas within the<br />
orthopaedic industry segments in which Össur operates.<br />
At the end of 2009, Össur had 349 patents granted in<br />
strategically selected countries within its portfolio, along<br />
with 364 pending patent applications. The Company’s<br />
trademark portfolio consists of 404 registered trademarks<br />
and 105 pending applications.<br />
bioMechanical and Medical<br />
platforMs<br />
Biomechanics is the application of mechanical princi-<br />
ples to the human body. In Össur’s case, it means that<br />
understanding biomechanical principles leads to products<br />
designed to meet the need for comfort, functionality<br />
and pain management. R&D’s biomechanical platform<br />
focuses on enhancing biomechanical research in order<br />
to design and validate orthotic and prosthetic devices<br />
based on current medical necessity.<br />
The Medical division of R&D focuses on clinical tests<br />
and the dissemination of clinical results, scientific collaboration<br />
with medical institutions, as well as providing<br />
clinical input for product development.<br />
25 <strong>annual</strong> report 09
Change language